• Revolution Medicines previously announced that the U.S. FDA accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma, supported by Phase 3 RASolute 302 data showing improved overall and progression-free survival versus standard chemotherapy.
• The drug’s Breakthrough Therapy and Orphan Drug designations, together with inclusion in the FDA Commissioner’s National Priority Voucher pilot program, underscore its potential to address a high unmet medical need in metastatic pancreatic cancer.
• We’ll now examine how daraxonrasib’s FDA priority review and strong Phase 3 data could reshape Revolution Medicines’ investment narrative in oncology.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Revolution Medicines Investment Narrative Recap

To own Revolution Medicines, you need to believe its RAS(ON) pipeline can turn today’s heavy cash burn and zero revenue into a durable oncology franchise. The new FDA review of daraxonrasib, backed by positive Phase 3 RASolute 302 results, strengthens the near term approval catalyst in metastatic pancreatic cancer, while also concentrating risk further on regulatory and commercial execution for this first potential product.

Among recent updates, the detailed RASolute 302 data presented in May 2026 and published in NEJM look especially relevant, as they underpin the daraxonrasib New Drug Application and the FDA’s priority review. Together with ongoing Phase 3 programs like RASolute 303 and 305, this reinforces the idea that clinical outcomes in pancreatic cancer are likely to be the key swing factor for how investors value Revolution Medicines over the next few years.

Yet, behind the excitement around daraxonrasib’s review, investors should also be aware of the company’s sustained US$1.6b to US$1.7b operating expense guidance and the risk that...

Revolution Medicines' narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies an earnings increase of about $1.2 billion from -$1.1 billion today.

Uncover how Revolution Medicines' forecasts yield a $133.70 fair value, a 29% downside to its current price.

Exploring Other Perspectives

Before this FDA update, the most cautious analysts were assuming only US$838.8m of revenue and US$158.7m of earnings by 2029, reminding you that expectations for how efficiently Revolution Medicines converts its RAS(ON) pipeline into profitable sales can differ sharply from the consensus view.

Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth 29% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.